- Home
- JEQ vs TCRX Comparison
JEQ vs TCRX Comparison
Compare JEQ & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEQ
- TCRX
- Stock Information
- Founded
- JEQ 1990
- TCRX 2018
- Country
- JEQ United States
- TCRX United States
- Employees
- JEQ N/A
- TCRX N/A
- Industry
- JEQ Air Freight/Delivery Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JEQ Consumer Discretionary
- TCRX Health Care
- Exchange
- JEQ Nasdaq
- TCRX Nasdaq
- Market Cap
- JEQ 88.1M
- TCRX 90.5M
- IPO Year
- JEQ N/A
- TCRX 2021
- Fundamental
- Price
- JEQ $7.27
- TCRX $1.46
- Analyst Decision
- JEQ
- TCRX Strong Buy
- Analyst Count
- JEQ 0
- TCRX 6
- Target Price
- JEQ N/A
- TCRX $9.50
- AVG Volume (30 Days)
- JEQ 32.0K
- TCRX 772.3K
- Earning Date
- JEQ 01-01-0001
- TCRX 05-06-2025
- Dividend Yield
- JEQ 7.05%
- TCRX N/A
- EPS Growth
- JEQ N/A
- TCRX N/A
- EPS
- JEQ N/A
- TCRX N/A
- Revenue
- JEQ N/A
- TCRX $4,421,000.00
- Revenue This Year
- JEQ N/A
- TCRX $68.86
- Revenue Next Year
- JEQ N/A
- TCRX $14.01
- P/E Ratio
- JEQ N/A
- TCRX N/A
- Revenue Growth
- JEQ N/A
- TCRX N/A
- 52 Week Low
- JEQ $4.99
- TCRX $1.02
- 52 Week High
- JEQ $6.39
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- JEQ 70.23
- TCRX 53.58
- Support Level
- JEQ $6.94
- TCRX $1.39
- Resistance Level
- JEQ $7.21
- TCRX $1.49
- Average True Range (ATR)
- JEQ 0.07
- TCRX 0.11
- MACD
- JEQ 0.00
- TCRX 0.02
- Stochastic Oscillator
- JEQ 96.25
- TCRX 88.24
About JEQ abrdn Japan Equity Fund Inc.
Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.